Loading...
Please wait, while we are loading the content...
Similar Documents
Viral Vectors for COVID-19 Vaccine Development
| Content Provider | MDPI |
|---|---|
| Author | Lundstrom, Kenneth |
| Copyright Year | 2021 |
| Description | Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK. |
| Starting Page | 317 |
| e-ISSN | 19994915 |
| DOI | 10.3390/v13020317 |
| Journal | Viruses |
| Issue Number | 2 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-02-19 |
| Access Restriction | Open |
| Subject Keyword | Viruses Virology Sars-cov-2 Covid-19 Vaccines Adenovirus Preclinical Immunization Clinical Trials Approved Vaccine |
| Content Type | Text |
| Resource Type | Article |
